LibiGel testosterone regulatory update

BioSante will begin 2 additional Phase III trials of LibiGel testosterone to treat hypoactive sexual desire disorder (HSDD) in menopausal women based on analysis of

Read the full 253 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE